Tivozanib is a potent inhibitor of VEGFR-1, 2 and 3 (IC50 = 0.21, 0.16 and 0.24 nM respectively). Promising anticancer agent in several different tumor types, including breast, lung and colorectal.
Product Specification
| Alternative Name: | AV-951, KRN-951 |
| |
| Formula: | C22H19ClN4O5 |
| |
| MW: | 454.9 |
| |
| CAS: | 475108-18-0 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Identity: | Determined by EM-MS, NMR |
| |
| Appearance: | White powder. |
| |
| Solubility: | Soluble in DMSO (20mg/ml) or ethanol (<1mg/ml). |
| |
| Shipping: | Ambient |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | VEGF receptors are receptors for vascular endothelial growth factor. There are three main subtypes of VEGFR, numbered 1, 2 and 3. Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the formation of the circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
